PeterGMaslakMD

Hematology • Buffalo, NY

Professor of Oncology

Join to view full profile

Dr. Maslak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maslak's full profile

Already have an account?

Office
66 Elm St
Buffalo, NY 14203
Phone+1 716-845-8075

Fax+1 716-845-7748

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
University of MichiganResidency, Internal Medicine, 1984 - 1987
Icahn School of Medicine at Mount SinaiClass of 1984

Certifications & Licensure

NY State Medical License 1987 - 2026
NJ State Medical License 2018 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission Start of enrollment: 1994 Mar 01
Completed
Phase 2
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Start of enrollment: 1996 Jul 01
Completed
Phase 2
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer Start of enrollment: 2000 May 01
Completed
Phase 2
Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia Start of enrollment: 2000 Apr 01
Completed
Phase 1
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia Start of enrollment: 2007 Sep 01
Terminated
Phase 2
WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2010 Dec 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients ...
Megan M Herr, Sophia R Balderman, Paul K Wallace, Yali Zhang, Joseph D Tario Jr
Transplantation and Cellular Therapy. 2024-08-01
Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation.
Giovanna Melica, Elaina Preston, Meighan Palazzo, Kenneth Seier, Florent Malard
Bone Marrow Transplantation. 2024-05-01
20 citations
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Todd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, Neeta Pandit-Taskar, Mark G Frattini
Clinical Cancer Research. 2022-05-13

Press Mentions

Pioneering Hematology/Oncology Expert Joins Roswell Park in Vice Chair RoleMarch 20th, 2023
Experts in Transplantation, Engineered Cells and Pediatrics Join Growing Roswell Park Cell Therapy ProgramDecember 7th, 2023
Inside Roswell Park's Big Bet on Cell Therapy and What That Means for Cancer CareApril 4th, 2024

Professional Memberships

American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
International Society for Advancement of Cytometry
Member
International Society for Cell & Gene Therapy
Member